The 34th International Symposium on ALS/MND arrived at a moment of real momentum in ALS research. The field has seen a significant expansion in genetic understa...
Continue reading
As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis...
Continue reading
Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies Sano Genetics launches ‘Ligh...
Continue reading
In the ever-evolving landscape of healthcare, precision medicine trials stand out as a beacon of personalised treatment, tailored to the unique genetic and envi...
Continue reading
As precision medicine advances from concept to clinical practice, its economic implications are becoming a central question for sponsors, health systems, and po...
Continue reading
ALS remains one of the most challenging neurodegenerative diseases, with limited treatment options and a progressive course that affects motor function, breathi...
Continue reading
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a complex liver disease characterized by fa...
Continue reading
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring David Ochoa, Platform Coordinator at Open Targets, explores the significance of human genetics ...
Continue reading
As precision medicine trials increasingly depend on genetic eligibility criteria, the process of testing, interpreting results, and guiding patients through the...
Continue reading
Genetic testing has become a defining capability in biotechnology and pharmaceutical development. By revealing the specific genetic variants that influence dise...
Continue reading